Kathleen M. McCarten

Author

Also Known As

K M McCarten, K McCarten, K. M. McCarten, K. McCarten, K.M. McCarten, KATHLEEN MCCARTEN, Kathleen M McCarten, Kathleen M. McCarten, Kathleen McCarten, Kathleen Mccarten

113

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Brown University Children's Oncology Group Roswell Park Comprehensive Cancer Center University of Florida Rhode Island Hospital

About

Kathleen M. McCarten is an author at Brown University specializing in medicine, oncology, and pediatrics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	17	659
2	Health Sciences	7	7	202
3	Anatomy	1	1	10
4	Applied Physiology	1	1	34
5	Athletic Training	1	1	34

Kathleen M. McCarten

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031 Debra L. Friedman, Lu Chen, Suzanne L. Wolden, Journal of Clinical Oncology	2014	259
Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma Sharon M. Castellino, Qinglin Pei, Susan K. Parsons, New England Journal of Medicine	2022	150
Disease Progression in Hutchinson-Gilford Progeria Syndrome: Impact on Growth and Development Leslie B. Gordon, Kathleen M. McCarten, Anita Giobbie‐Hurder, PEDIATRICS	2007	133
Follow-up compliance after emergency department evaluation A. Roy Magnusson, Jerris R. Hedges, Mark Vanko, Annals of Emergency Medicine Emergency ResponseEmergency Department EvaluationPatient SafetyEmergency Department AdministrationOutcomes Research	1993	123
BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group Kara M. Kelly, Richard Sposto, Raymond J. Hutchinson, Blood	2010	116
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial Peter D. Cole, Kathleen M. McCarten, Qinglin Pei, The Lancet Oncology Lymphoid NeoplasiaOncologyRefractory HodgkinPediatric HematologyCancer Treatment	2018	83
Level of In Utero Cocaine Exposure and Neonatal Ultrasound Findings Deborah A. Frank, Kathleen M. McCarten, Caroline D. Robson, PEDIATRICS	1999	76
Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group Kara M. Kelly, Peter D. Cole, Qinglin Pei, British Journal of Haematology	2019	74
Long-Term Followup of Primary Nonrefluxing Megaureter Dacia Di Renzo, Liza Aguiar, Valentina Cascini, The Journal of Urology	2013	66
Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group Cindy L. Schwartz, Lu Chen, Kathleen M. McCarten, Pediatric Blood & Cancer	2016	60

Page 1